✦ LIBER ✦

Exemestane for Breast-Cancer Prevention in Postmenopausal Women

✍ Scribed by Litton, J.K.

Book ID: 122713380
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 56 KB
Volume: 23
Category: Article
ISSN: 1043-321X
DOI: 10.1016/j.breastdis.2012.06.008

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bone density and structure in healthy po

Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial

✍ Angela M Cheung; Lianne Tile; Savannah Cardew; Sandhya Pruthi; John Robbins; Geo 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 221 KB

Exemestane for postmenopausal women at i

Exemestane for postmenopausal women at increased risk of breast cancer

✍ Jame Abraham 📂 Article 📅 2011 🏛 Frontline Medical Communications, Inc. 🌐 English ⚖ 621 KB

Exemestane for breast cancer prevention:

Exemestane for breast cancer prevention: low QOL impact

📂 Article 📅 2014 🏛 Adis International Limited (now part of Wolters Kl ⚖ 199 KB

Exemestane for breast cancer prevention:

Exemestane for breast cancer prevention: low QOL impact

📂 Article 📅 2014 🏛 Adis International Limited (now part of Wolters Kl ⚖ 199 KB

National Cancer Institute of Canada Clin

National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: Evaluation of Exemestane to Prevent Breast Cancer in Postmenopausal Women

✍ Paul E. Goss; Harriet Richardson; Rowan Chlebowski; Dianne Johnston; Gloria E. S 📂 Article 📅 2007 🏛 CIG Media Group, LP. 🌐 English ⚖ 94 KB

Arzoxifene for prevention of fractures a

Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women

✍ Steven R Cummings; Michael McClung; Jean-Yves Reginster; David Cox; Bruce Mitlak 📂 Article 📅 2010 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 97 KB

## Abstract Arzoxifene is a selective estrogen receptor modulator (SERM) that has been shown to be more potent in preclinical testing than currently available agents. Its effects on clinical outcomes are not known. In a randomized, blinded trial, women aged 60 to 85 years with osteoporosis, defined